<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30302857</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>12</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1349-7006</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer science</Title>                <ISOAbbreviation>Cancer Sci.</ISOAbbreviation>            </Journal>            <ArticleTitle>Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.1111/cas.13828</ELocationID>            <Abstract>                <AbstractText>Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare subtype of DLBCL with limited data on patterns of failure. This multicenter study aimed to define the optimum treatment strategy and patterns of failure for PB-DLBCL patients. We retrospectively reviewed data on 108 PB-DLBCL patients from 21 Chinese medical centers. Only patients with localized disease (involvement of breast and localized lymph nodes) were included. After a median follow-up of 3.2 years, 32% of patients developed progression or relapse. A continuous pattern of relapse was observed, characterized by frequent late relapses in the contralateral breast and central nervous system (CNS). Although rituximab significantly reduced the overall cumulative risk of progression or relapse (5-year cumulative risk 57% vs 24%, P = .029), it had limited effect on the reduction of breast relapse (P = .46). Consolidative radiotherapy significantly decreased the risk of breast relapse, even in the subgroup of patients treated with rituximab (5-year cumulative risk 21.2% vs 0%, P = .012). A continuous risk of CNS progression or relapse up to 8.2 years from diagnosis was observed (10-year cumulative risk 28.3%), with a median time to CNS relapse of 3.1 years. Neither rituximab nor prophylactic intrathecal chemotherapy significantly decreased the risk of CNS relapse. In summary, our study indicates that PB-DLBCL has a continuous pattern of relapse, especially with frequent late relapses in the CNS and contralateral breast. Rituximab and RT confer complementary benefit in the reduction of relapse. However, neither the addition of rituximab nor prophylactic intrathecal chemotherapy could effectively prevent CNS relapse for PB-DLBCL patients.</AbstractText>                <CopyrightInformation>© 2018 The Authors. Cancer Science published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Cancer Association.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Shaoxuan</ForeName>                    <Initials>S</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-4422-1388</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Song</LastName>                    <ForeName>Yuqin</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sun</LastName>                    <ForeName>Xiuhua</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Su</LastName>                    <ForeName>Liping</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Cancer Hospital of Shanxi Province, Taiyuan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Wei</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jia</LastName>                    <ForeName>Jing</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital and Institute, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bai</LastName>                    <ForeName>Ou</ForeName>                    <Initials>O</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, The First Hospital of Jilin University, Jilin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Sheng</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liang</LastName>                    <ForeName>Rong</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Xijing Hospital, The Fourth Military Medical University, Xi'an, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Xiaoling</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Liaoning Cancer Hospital and Institute, Shenyang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Huilai</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Gao</LastName>                    <ForeName>Yuhuan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhang</LastName>                    <ForeName>Weijing</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, 307 Hospital of Chinese People's Liberation Army, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xiao</LastName>                    <ForeName>Xiubin</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, 307 Hospital of Chinese People's Liberation Army, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bao</LastName>                    <ForeName>Huizheng</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Jilin Cancer Hospital, Changchun, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Ningju</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ren</LastName>                    <ForeName>Hanyun</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Peking University First Hospital, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cen</LastName>                    <ForeName>Xinan</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Peking University First Hospital, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yang</LastName>                    <ForeName>Shun'e</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Xinjiang Cancer Hospital, Wulumuqi, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Yu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, The General Hospital of Chinese People's Liberation Army, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yinan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, The People's Hospital of Tangshan City, Tangshan, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Yalan</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, Baotou Cancer Hospital, Baotou, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Aichun</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, The Third Hospital of Harbin Medical University, Haerbin, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Jingwen</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Shi</LastName>                    <ForeName>Yuankai</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yuan</LastName>                    <ForeName>Ming</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Illinois Institute of Technology, Chicago, Illinois.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Yufu</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>He</LastName>                    <ForeName>Xiaohui</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <Agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</Agency>                    <Country/>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>09</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Cancer Sci</MedlineTA>            <NlmUniqueID>101168776</NlmUniqueID>            <ISSNLinking>1347-9032</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast</Keyword>            <Keyword MajorTopicYN="N">diffuse large B-cell lymphoma</Keyword>            <Keyword MajorTopicYN="N">radiotherapy</Keyword>            <Keyword MajorTopicYN="N">relapse</Keyword>            <Keyword MajorTopicYN="N">rituximab</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>06</Month>                <Day>25</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>09</Month>                <Day>27</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>11</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30302857</ArticleId>            <ArticleId IdType="doi">10.1111/cas.13828</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>